SummaryThis prediction ended on 02.10.23 with a price of €0.94. The price of Esperion Therapeutis.Inc. has decreased during the runtime of the prediction. Compared to the start price this resulted in a performance of -24.48%. thomasw has 50% into this prediction
Esperion Therapeutics, Inc. (NASDAQ: ESPR) is a biopharmaceutical company primarily focused on the development and commercialization of innovative lipid management therapies to address the unmet medical needs of patients with high cholesterol. With its flagship products, NEXLETOL® and NEXLIZET®, the company aims to provide alternative treatment options for individuals who cannot tolerate statins or require additional LDL-C lowering despite statin therapy. Esperion is driven by its commitment to improve cardiovascular health globally and maintains a steadfast dedication to researching and developing advanced cholesterol-lowering therapies.
Performance without dividends (%)
|iShares Core DAX®||2.122%||10.227%|
|iShares Nasdaq 100||1.636%||4.583%|
|iShares Nikkei 225®||-0.215%||3.810%|
|iShares S&P 500||1.321%||4.686%|